Syncona

Venture Capital

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.

Portfolio

companies

Portfolio companies

Freeline

Freeline develops curative gene therapies for chronic systemic diseases.

Team

Chris Hollowood

Chief Investment Officer

Recent investments

Series C30 June 2020

£96.0M

Freeline secures £96m in extended Series C funding led by Novo Holdings, Eventide Asset Management and Wellington Management Company

BioTech

The biotechnology firm has raised £96m in new capital to advance its gene therapy pipeline and manufacturing capabilities.

"The potential of gene therapy to change patients’ lives has never been greater and we are delighted to have leading US and European biotechnology investors join us in this extended Series C financing,"

— Theresa Heggie, CEO

Freeline—London, UK

Novo Holdings + 6 others